Fujifilm Diosynth to establish viral vector manufacturing in Boston

By The Science Advisory Board staff writers

January 5, 2021 -- Contract development and manufacturing organization (CDMO) Fujifilm Diosynth Biotechnologies will establish a new process development and manufacturing facility in Watertown, MA, near Boston, for viral vectors and advanced therapies.

Funded via a $40 million investment by Fujifilm Corporation, the new facility will be the third location for viral vector CDMO services provided by Fujifilm Diosynth Biotechnologies, according to the company. Process development operations are slated to commence in the fall of 2021, with contract manufacturing services for early-phase clinical trials expected to begin at the facility in the fall of 2023.

The facility will house experimental and analytical equipment for viral vector and advanced therapy process development, the firm said.


Copyright © 2021 scienceboard.net
 
To access all The ScienceBoard content create a free account now:


Email Address:  

First Name:

Last Name:

Learn about ScienceBoard

Get the latest life sciences research and industry news, delivered straight to your inbox, for free.

Why subscribe?

ScienceBoard is uniquely focused on the business of research, addressing the biggest problems that the biomedical industry face. You’ll get breaking news, events coverage, and deep dives into the science that drives innovation, delivered to your inbox daily.


Letter from the Editor Please send me twice-weekly roundups of all the latest life research and industry news.
SAB Announcements Please send me the latest announcements from The Science Advisory Board and their partners.
Spotlight Receive notifications about new content, services, or educational resources designed to help you sharpen your skills and grow professionally.
 
I have read and agree to the privacy policy and terms of service and wish to opt-in for ScienceBoard.net.

Already have an account? Sign in here